Preview

Пульмонология

Расширенный поиск

Клинические рекомендации Европейского респираторного общества и Европейского общества торакальных хирургов по ведению больных со злокачественной мезотелиомой плевры

https://doi.org/10.18093/0869-0189-2010-3-11-29

Полный текст:

Список литературы

1. Robinson B.W., Musk A.W., Lake R.A. Malignant mesothelioma. Lancet 2005; 366: 397-408.

2. Hodgson J.T., McElvenny D.M., Darnton A.J. et al. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br. J. Cancer 2005; 92: 587-593.

3. Pass H.I., Vogelzang N., Hahn S. et al. Malignant pleural mesothelioma. Curr. Probl. Cancer 2004; 28: 93-174.

4. Scherpereel A. Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma. Respir. Med. 2007; 101: 1265-1276.

5. Scherpereel A. [The experts' conference of the Societe de Pneumologie de Langue Francaise (SPLF) on malignant pleural mesothelioma (MPM): useful and necessary recommendations]. Rev. Mal. Respir. 2006; 23: 11S5-11S6.

6. Stahel R.A., Weder W., Felip E. Malignant pleural mesothelioma: ESMO clinical recommendations for diag nosis, treatment and followup. Ann. Oncol. 2008; 19 (suppl. 2): ii43-ii44.

7. British Thoracic Society Standards of Care Committee, BTS statement on malignant mesothelioma in the UK, 2007. Thorax 2007; 62 (suppl. 2): ii1-ii19.

8. Guyatt G., Gutterman D., Baumann M.H. et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College Of Chest Physicians task force. Chest 2006; 129: 174-181.

9. Wagner J.C., Sleggs C.A., Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br. J. Industr. Med. 1960; 17: 260-271.

10. Goldberg M., Imbernon E., Rolland P. et al. The French National Mesothelioma Surveillance Program. Occup. Environ. Med. 2006; 63: 390-395.

11. Bourdes V., Boffetta P., Pisani P. Environmental exposure to asbestos and risk of pleural mesothelioma: review and metaanalysis. Eur. J. Epidemiol. 2000; 16: 411-417.

12. Maule M.M., Magnani C., Dalmasso P. et al. Modeling mesothelioma risk associated with environmental asbestos exposure. Environ. Hlth Perspect. 2007; 115: 1066-1071.

13. Iwatsubo Y., Pairon J.C., Boutin C. et al. Pleural mesothelioma: doseresponse relation at low levels of asbestos exposure in a French populationbased casecontrol study. Am. J. Epidemiol. 1998; 148: 133-142.

14. Lanphear B.P., Buncher C.R. Latent period for malignant mesothelioma of occupational origin. J. Occup. Med. 1992; 34: 718-721.

15. Reid A., de Klerk N., Ambrosini G. et al. The additional risk of malignant mesothelioma in former workers and residents of Wittenoom with benign pleural disease or asbestosis. Occup. Environ. Med. 2005; 62: 665-659.

16. Roushdy:Hammady I., Siegel J., Emri S. et al. Geneticsus ceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 2001; 357: 444-445.

17. Dogan A.U., Baris Y.I., Dogan M. et al. Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey. Cancer Res. 2006; 66: 5063-5068.

18. Lin R.T., Takahashi K., Karjalainen A. et al. Ecological association between asbestosrelated diseases and historical asbestos consumption: an international analysis. Lancet 2007; 369: 844-849.

19. Robinson B.W., Lake R.A. Advances in malignant mesothelioma. N. Engl. J. Med. 2005; 353: 1591-1603.

20. Segura O., Burdorf A., Looman C. Update of predictions of mortality from pleural mesothelioma in the Netherlands. Occup. Environ. Med. 2003; 60: 50-55.

21. Montanaro F., Bray F., Gennaro V. et al. Pleural mesothelioma incidence in Europe: evidence of some deceleration in the increasing trends. Cancer Causes Control 2003; 14: 791-803.

22. Pelucchi C., Malvezzi M., La Vecchia C. et al. The Mesothelioma epidemic in Western Europe: an update. Br. J. Cancer 2004; 90: 1022-1024.

23. De Vuyst P., Karjalainen A., Dumortier P. et al. Guidelines for mineral fibre analyses in biological samples: report of the ERS Working Group. Eur. Respir. J. 1998; 11: 1416-1426.

24. Fasola G., Belvedere O., Aita M. et al. Lowdose computed tomography screening for lung cancer and pleural mesothelioma in an asbestosexposed population: baseline results of a prospective, nonrandomized feasibility trial - an Alpeadria Thoracic Oncology Multidisciplinary Group Study (ATOM 002). Oncologist 2007; 12: 1215-1224.

25. Scherpereel A., Lee Y.C. Biomarkers for mesothelioma. Curr. Opin. Pulm. Med. 2007; 13: 339-443.

26. Park E.K., Sandrini A., Yates D.H. et al. Soluble mesothe linrelated protein in an asbestosexposed population: the dust diseases board cohort study. Am. J. Respir. Crit. Care Med. 2008; 178: 832-837.

27. van Meerbeeck J.P., Hillerdal G. Screening for mesothe lioma: more harm than good? Am. J. Respir. Crit. Care Med. 2008; 178: 781-782.

28. Eibel R., Tuengerthal S., Schoenberg S.O. The role of new imaging techniques in diagnosis and staging of malignant pleural mesothelioma. Curr. Opin. Oncol. 2003; 15: 131-138.

29. Wang Z.J., Reddy G.P., Gotway M.B. et al. Malignant pleu ral mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics 2004; 24: 105-119.

30. Francis R.J., Byrne M.J., van der Schaaf A.A. et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3dimensional volumebased analysis of serial 18F FDG PET scans. J. Nucl. Med. 2007; 48: 1449-1458.

31. Flores R.M. The role of PET in the surgical management of malignant pleural mesothelioma. Lung Cancer 2005; 49 (suppl. 1): S27-S32.

32. Travis W.D., Brambilla E., Muller:Hermelink H.K. et al., eds. World Health Organization classification of tumours. Pathology and genetics. Tumours of the lung, pleura, thymus and heart. Lyon: IARC; 2004.

33. Wittekind Ch., Greene F.L., Hutter R.V.P. et al., eds. UICC, International Union Against Cancer. TNM atlas. Illustrated guide to the TMN classification of malignant tumours. 5th ed. Berlin: Springer; 2004. 169-176.

34. van Meerbeeck J.P., Boyer M. Consensus report: pretreat ment minimal staging and treatment of potentially resectable malignant pleural mesothelioma. Lung Cancer 2005; 49 (suppl. 1): S123-S127.

35. Steele J.P. Prognostic factors for mesothelioma. Hematol. Oncol. Clin. N. Am. 2005; 19: 1041-1052.

36. Spirtas R., Connelly R.R., Tucker M.A. Survival patterns for malignant mesothelioma: the SEER experience. Int. J. Cancer 1988; 41: 525-530.

37. Robinson B.W., Creaney J., Lake R. et al. Mesothelinfam ily proteins and diagnosis of mesothelioma. Lancet 2003; 362: 1612-1616.

38. Pass H.I., Lott D., Lonardo F. et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N. Engl. J. Med. 2005; 353: 1564-1573.

39. Grigoriu B.D., Scherpereel A., Devos P. et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin. Cancer Res. 2007; 13: 2928-2935.

40. Herndon J.E., Green M.R., Chahinian A.P. et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998; 113: 723-731.

41. Curran D., Sahmoud T., Therasse P. et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J. Clin. Oncol. 1998; 16: 145-152.

42. van Meerbeeck J.P., Gaafar R., Manegold C. et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J. Clin. Oncol. 2005; 23: 6881-6889.

43. Bottomley A., Coens C., Efficace F. et al. Symptoms and patientreported wellbeing: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTCNCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2007; 25: 5770-5776.

44. Waller D.A., Morritt G.N., Forty J. Videoassisted thoracoscopic pleurectomy in the management of malignant pleu ral effusion. Chest 1995; 107: 1454-1456.

45. Soysal O., Karaoglanoglu N., Demiracan S. et al. Pleurectomy / decortication for palliation in malignant pleural mesothelioma: results of surgery. Eur. J. Cardiothorac. Surg. 1997; 11: 210-213.

46. Halstead J.C., Lim E., Venkateswaran R.M. et al. Improved survival with VATS pleurectomydecortication in advanced malignant mesothelioma. Eur. J. Surg. Oncol. 2005; 31: 314-320.

47. Nakas A., Martin Ucar A.E., Edwards J.G. et al. The role of video assisted thoracoscopic pleurectomy / decortication in the therapeutic management of malignant pleural mesothelioma. Eur. J. Cardiothorac. Surg. 2008; 33: 83-88.

48. Martin:Ucar A.E., Edwards J.G., Rengajaran A. et al. Palliative surgical debulking in malignant mesothelioma. Predictors of survival and symptom control. Eur. J. Cardiothorac. Surg. 2001; 20: 1117-1121.

49. Sugarbaker D.J., Jaklitsch M.T., Bueno R. et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J. Thorac. Cardiovasc. Surg. 2004; 128: 138-146.

50. Rusch V.W., Rosenzweig K., Venkatraman E. et al. A phase II trial of surgical resection and adjuvant highdose hemithoracic radiation for malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 2001; 122: 788-795.

51. Weder W., Stahel R.A., Bernhard J. et al. Multicenter trial of neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann. Oncol. 2007; 18: 1196-1202.

52. Boutin C., Rey F., Viallat J.R. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest 1995; 108: 754-758.

53. O'Rourke N., Garcia J.C., Paul J. et al. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother. Oncol. 2007; 84: 18-22.

54. Muirhead R., O'Rourke N. Drain site radiotherapy in malignant pleural mesothelioma: a wasted resource. Eur. Respir. J. 2007; 30: 1021.

55. Chapman E., Berenstein E., Dieґguez M. et al. Radio therapy for malignant pleural mesothelioma. Cochrane Database Syst. Rev. 2006; 3: CD003880.

56. Baldini E.H. External beam radiation therapy for the treat ment of pleural mesothelioma. Thorac. Surg. Clin. 2004; 14: 543-548.

57. Allen A.M., Czerminska M., Janne P.A. et al. Fatal pneu monitis associated with intensitymodulated radiation therapy for mesothelioma. Int. J. Radiat. Oncol. Biol. Phys. 2006; 65: 640-645.

58. Berghmans T., Brechot J.M., Robinet G. et al. [Chemo therapy of malignant pleural mesothelioma.] Rev. Mal. Respir. 2006; 23: 11S57-11S70.

59. Ellis P., Davies A.M., Evans W.K. et al. The Use of Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma. A Quality Initiative of the Program in Evidencebased Care (PEBC), Cancer Care Ontario (CCO). October 2005. www.cancercare.on.ca/pdf/pebc7 141f.pdf

60. Berghmans T., Paesmans M., Lalami Y. et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with metaanalysis. Lung Cancer 2002; 38: 111-121.

61. Berghmans T.L.J., Mascaux C., Meert A.P. et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with metaanalysis, 2003: 245-256.

62. Muers M.F., Stephens R.J., Fisher P. et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomized trial. Lancet 2008; 371: 1685-1694.

63. Vogelzang N.J., Rusthoven J.J., Symanowski J. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2003; 21: 2636-2644.

64. Manegold C., Symanowski J., Gatzemeier U. et al. Second line (poststudy) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann. Oncol. 2005; 16: 923-927.

65. Giaccone G., O'Brien M.E., Byrne M.J. et al. Phase II trial of ZD0473 as secondline therapy in mesothelioma. Eur. J. Cancer 2002; 38 (suppl. 8): S19-S24.

66. Harvey V.J., Slevin M.L., Ponder B.A. et al. Chemotherapy of diffuse malignant mesothelioma. Phase II trials of sin gleagent 5fluorouracil and adriamycin. Cancer 1984; 54: 961-964.

67. Porta C., Zimatore M., Bonomi L. et al. Raltitrexedoxali platin combination chemotherapy is inactive as second line treatment for malignant pleural mesothelioma patients. Lung Cancer 2005; 48: 429-434.

68. Sorensen P.G., Bach F., Bork E. et al. Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat. Rep. 1985; 69: 1431-1432.

69. Fennell D.A., Steele J.P., Shamash J. et al. Efficacy and safety of first or secondline irinotecan, cisplatin, and mitomycin in mesothelioma. Cancer 2007; 109: 93-99.

70. Sorensen J.B., Sundstrom S., Perell K. et al. Pemetrexed as secondline treatment in malignant pleural mesothelioma after platinumbased firstline treatment. J. Thorac. Oncol. 2007; 2: 147-152.

71. Jassem J., Ramlau R., Santoro A. et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J. Clin. Oncol. 2008; 26: 1698-1704.

72. DeVita V.T. Jr. The James Ewing lecture. The relationship between tumor mass and resistance to chemotherapy. Implications for surgical adjuvant treatment of cancer. Cancer 1983; 51: 1209-1220.

73. Skipper H.E., Schabel F.M. Jr., Wilcox W.S. Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with ''curability'' of experi mental leukemia. Cancer Chemother. Rep. 1964; 35: 1-111.

74. Skipper H.E. Laboratory models: some historical perspec tive. Cancer Treat. Rep. 1986; 70: 3-7.

75. O'Brien M.E., Watkins D., Ryan C. et al. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann. Oncol. 2006; 17: 270-275.

76. Ramalingam S.S., Belani C.P., Ruel C. et al. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J. Thorac. Oncol. 2009; 4: 97-101.

77. Stebbing J., Powles T., McPherson K. et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 2009; 63: 94-97.

78. Baas P., Boogerd W., Dalesio O. et al. Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 2005; 48: 291-296.

79. Karrison T.K.H., Gandara D.R., Lu C. et al. Final analysis of a multicenter, doubleblind, placebocontrolled, ran domized phase II trial of gemcitabine / cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM). J. Clin. Oncol. 2007; 25 (suppl. 20): 18S.

80. Govindan R., Kratzke R.A., Herndon J.E. II et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin. Cancer Res. 2005; 11: 2300-2304.

81. Mathy A., Baas P., Dalesio O. et al. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 2005; 50: 83-86.

82. Millward M.P.F., Byrne M., Powell A. et al. Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma. Proc. Am. Soc. Clin. Oncol. 2003; 22: 228.

83. Villano J.L., Hussain A.N., Stadler W.M. et al. A phase II trial of imatinib mesylate in patients with malignant mesothelioma. Proc. Am. Soc. Clin. Oncol. 2004; 22 (suppl. 15): 14s.

84. Garland L.L., Rankin C., Gandara D.R. et al. Phase II study of erlotinib in patients with malignant pleural meso thelioma: a Southwest Oncology Group Study. J. Clin. Oncol. 2007; 25: 2406-2413.

85. van Klaveren R.J., Aerts J.G., de Bruin H. et al. Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. Lung Cancer 2004; 43: 63-69.

86. Byrne M.J., Nowak A.K. Modified RECIST criteria for assessment of response in malignant pleural mesothe lioma. Ann. Oncol. 2004; 15: 257-260.

87. Nowak A.K. CT, RECIST, and malignant pleural mesothelioma. Lung Cancer 2005; 49 (suppl. 1): S37-S40.

88. Young H., Baum R., Cremerius U. et al. Measurement of clinical and subclinical tumour response using [18F]fluo rodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur. J. Cancer 1999; 35: 1773-1782.

89. Hollen P.J., Gralla R.J., Liepa A.M. et al. Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSSMeso. Support Care Cancer 2006; 14: 11-21.

90. Senan S. Indications and limitations of radiotherapy in malignant pleural mesothelioma. Curr. Opin. Oncol. 2003; 15: 144-147.

91. Maasilta P. Deterioration in lung function following hemithorax irradiation for pleural mesothelioma. Int. J. Radiat. Oncol. Biol. Phys. 1991; 20: 433-438.

92. Steele J.P., Klabatsa A., Fennell D.A. et al. Prognostic factors in mesothelioma. Lung Cancer 2005; 49 (suppl. 1): S49-S52.

93. Krug L.M.K., Pass H., Rusch V.W. et al. A multicenter U.S. trial of neoadjuvant pemetrexed plus cisplatin (PC) followed by extrapleural pneumonectomy (EPP) and hemithoracic radiation (RT) for stage I-III malignant pleural mesothelioma (MPM). Proc. Am. Soc. Clin. Oncol. 2007; 25 (suppl. 20): 18S.

94. Van Schil P., Hasan B., Maat A. et al. EORTC 08031. In: The 9th international conference of the International Mesothelioma Interest Group. Amsterdam; 2008. 174.

95. Monneuse O., Beaujard A.C., Guibert B. et al. Longterm results of intrathoracic chemohyperthermia (ITCH) for the treatment of pleural malignancies. Br. J. Cancer 2003; 88: 1839-1843.

96. van Ruth S., Baas P., Haas R.L. et al. Cytoreductive surgery combined with intraoperative hyperthermic intrathoracic chemotherapy for stage I malignant pleural mesothe lioma. Ann. Surg. Oncol. 2003; 10: 176-182.

97. Xia H., Karasawa K., Hanyu N. et al. Hyperthermia combined with intrathoracic chemotherapy and radiotherapy for malignant pleural mesothelioma. Int. J. Hypertherm. 2006; 22: 613-621.

98. Nowak A.K., Stockler M.R., Byrne M.J. Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module. J. Clin. Oncol. 2004; 22: 3172-3180.

99. Ahmedzai S., Clayson H. Palliative care for mesothelioma. In: O'Byrne K., Rusch V., eds. Malignant pleural mesothelioma. Oxford: Oxford University Press; 2006. 412-418.

100. Corner J., Plant H., A'Hern R. et al. Nonpharmacological intervention for breathlessness in lung cancer. Palliat. Med. 1996; 10: 299-305.


Для цитирования:


Шерперил А..., Астул П..., Баас П..., Бергманс Т..., Клейсон Х..., Де Вуйст П..., Динеманн Х..., Галатьесалле Ф..., Хеннеквин К..., Хиллердал Д..., Ле Пешо К..., Мутти Л..., Пейрон Д.К., Стайел Р..., Ван Хутте П..., Ван Меербек Д..., Уоллер Д..., Ведер В... Клинические рекомендации Европейского респираторного общества и Европейского общества торакальных хирургов по ведению больных со злокачественной мезотелиомой плевры. Пульмонология. 2010;(3):11-29. https://doi.org/10.18093/0869-0189-2010-3-11-29

Просмотров: 124


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)